EGRX News and Press, Eagle Pharmaceuticals Inc. From 03/02/21

-- Q4 2020 net income was $0.62 per basic and $0.60 per diluted share and adjusted non-GAAP net income was $0.98 per basic and $0.96 per diluted share – -- FY 2020 net income was $0.89 per basic and $0.87 per diluted share and adjusted non-GAAP net income was $3.62 per ba...

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the market opens. Scott Tarriff, Chief Executive ...

Eagle Pharmaceuticals ([[EGRX]] +4.7%) expects to submit a full response to the complete response letter (“CRL”) received from the FDA for its Abbreviated New Drug Application (“ANDA”) for vasopressin.The company intends to run an additional short-duratio...

-Company Expects It Will Have 180 Days of Exclusivity- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (&#...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the District of Delaware (the “Court”) postponed the February 1, 2021 vasopressin trial between...

Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP gained 14.7% net in 2020, which compares against the Russell 2000 Index ...

Eagle Pharmaceuticals (EGRX) announces that the United States District Court postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern.The trial is...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovat...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows: ...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32 nd Annual Virtual Healthcare Conference is now available for viewing via the link below: ...